



MEETING OF THE NATIONAL COMPETENT AUTHORITIES ON PRICING AND REIMBURSEMENT AND PUBLIC HEALTHCARE PAYERS (NCAPR)

12 DECEMBER 2023, 09H45-16H00 CET

**MANSHOLT ROOM CHARLEMAGNE BUILDING, RUE DE LA LOI 170, 1040 BRUSSELS
(PHYSICAL)**

AGENDA

09.30 – 09.45 Registration and coffee

09.45 – 10.00 Opening

- *Spanish Presidency: Cesar Hernández, Director General for the Common Portfolio of SNS and Pharmacy, Ministry of Health*
- *European Commission: Rainer Becker, Director SANTE D (Medical Products and Innovation)*

Adoption of the meeting notes from the last NCAPR Plenary

10.00 - 11.30 Non-paper on the strategic direction for the NCAPR

At the last Plenary meeting of the NCAPR in Madrid (26 October 2023), a discussion was held on “setting the strategic direction for EU-level cooperation on medicine pricing and reimbursement policies”. There, the need for a solid framework of governance, clear identity and producing concrete deliverables was stressed. Some members also proposed intensifying the dialogue with other authorities in the medicine’s lifecycle and their groups, as well as moving to a two-tiered configuration (strategic and technical). Concrete examples of specific activities that could be part of a Joint Action supporting the NCAPR work and its objectives were shared. In this session, the objective is to agree on a non-paper reflecting these conclusions, based on a draft prepared by the Spanish Presidency, which will soon be shared with you.

- *Presentation of the non-paper. Spanish Presidency*
- *Discussion*
- *Conclusion*

11.30 - 12.30 Access to antimicrobials

In this session, we will focus on initiatives having the objective to increase access to antibiotics. Our colleagues from HERA will present an initiative under EU4Health aiming to improve access to recently authorised antimicrobials under the form of a revenue guarantee scheme, and collect insights on how this may impact your negotiations and interact with national P&R procedures. We will also receive an

update on the Access to antibiotics work package under the Joint Action on Antimicrobial Resistance (JAMRAI).

- *Revenue Guarantee Scheme for recently authorised antimicrobials. Damiët Onderstal, Policy Officer (HERA)*
- *Joint Procurement for antibiotics and treatments for respiratory viruses ahead of winter 2024-2025. Kelly Fortan, Procurement Expert, Andrea Borrell Vila, Legal Officer (HERA)*
- *Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (JAMRAI). Christine Ardal, Senior Researcher Norwegian Institute of Public Health (NIPH, NO)*
- *Discussion*
- *Conclusion*

12.30– 14.30

<<Lunch and networking>>

14.30 – 15.45 Ensuring budget sustainability through competition: a focus on biosimilars

One of the five priority areas identified by NCAPR members is to ensure budget sustainability through competition, inter alia by sharing best practices to encourage off-patent competition and encouraging the use of biosimilars. In this session, and in preparation of the back-to-back Biosimilar Multistakeholder event (13 December 2023 in Brussels), we will hear from different initiatives / policies aiming to improve awareness and access to biosimilars.

- *Update on the HMA Biosimilar Working Group activities. Esa Heinonen (FI)*
- *Tender for capacity building to support the uptake of biosimilars in a multi-stakeholder approach. François Janssens (DG SANTE)*
- *Recent developments in biosimilar policies: country examples*
 - *Tendering of biosimilars in Norway. Pal Rydstrom (NO)*
 - *Automatic substitution in Finland. Esa Heinonen (FI)*
- *Discussion and next steps*

15.45 - 16.00 Conclusions/ Next meeting

- *Spanish Presidency*
- *Belgian Presidency*
- *European Commission*

* * * * *